



*Eidos-sponsored Symposium*

## “TTR Stabilization for ATTR: Past, Present and Future”

Thursday, March 29 | 7:40am - 8:40am | Main Hall

### Chair

**Mathew Maurer, MD**  
Columbia University

### Moderator

**Daniel Judge, MD**  
Medical University of  
South Carolina

### Panelists

**Pablo Garcia-Pavia, MD, PhD**  
Hospital Universitario Puerta  
de Hierro Majadahonda

**Morie Gertz, MD**  
Mayo Clinic

**Stephen Heitner, MD**  
Oregon Health Sciences  
University

**Jose Nativi-Nicolau, MD**  
University of Utah

### About Eidos Therapeutics

Eidos Therapeutics is a clinical stage biopharmaceutical company based in San Francisco. Eidos is singularly focused on addressing the large and growing unmet need in transthyretin amyloidosis with AG10, a small molecule precision medicine that targets the disease at its source by stabilizing tetrameric transthyretin. Launched in 2016 and based on research at Stanford University, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment to market as quickly as possible. [eidostx.com](http://eidostx.com)

